Terry J. Fry
Pediatric Oncology Branch, CCR
National Cancer Institute
United States of America
Terry J. Fry received a B.A. from Colgate University in 1988 and an M.D. from Georgetown University in 1992. After completing a pediatric residency at Georgetown in 1995, he served as Chief Pediatric Resident. From 1996-1999, Dr. Fry undertook fellowship training in pediatric hematology and oncology at Johns Hopkins University. After postdoctoral training in the laboratory of Dr. Crystal Mackall, Dr. Fry established a research program focused on the immunology of stem cell transplantation as a platform for cancer immunotherapy. Dr. Fry became Chief of the Division of Blood and Marrow Transplantation at Children's National Medical Center in 2007, a position he held until 2010 when he returned to the Pediatric Oncology Branch as Head of the Hematologic Malignancies Section. He is a member of multiple societies including the American Society of Hematology, the American Association of Immunology and the American Society of Blood and Marrow Transplantation and was elected into the American Society of Clinical Investigation. He also serves in leadership positions in the Oncology Strategy Group in the Pediatric Blood and Marrow Transplant Consortium and the Cellular Therapy Committee in the Children's Oncology Group.
1. Translational development of chimeric antigen receptors for the treatment of pediatric leukemia, 2. Elucidation of the biologic principles involved in the immunotherapeutic targeting of pediatric leukemia, 3. Pediatric leukemia, 4. Immunotherapy, 5. Adoptive cell therapy.
Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD.
Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.
CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity.